Telomir Pharmaceuticals (TELO) said Monday that Andriy Mushak has been named as the company's fractional CFO, effective June 6, succeeding Alan Weichselbaum who has stepped down.
Telomir said in a regulatory filing that Weichselbaum's departure was not the result of any disagreement with the company on any matter relating to its operations, policies, or practices.
Mushak is a partner at LMAM Consulting Group, which has a consulting agreement with Telomir Pharmaceuticals. The company said he remains employed by LMAM under the terms of the agreement.